Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma

Research output: Contribution to journalReview article

Abstract

Radiofrequency ablation (RFA) is an effective local treatment for curative intent in patients with cirrhosis of the liver and hepatocellular carcinoma (HCC) with diameter <3 cm. Several meta-analyses have shown that RFA and surgical resection are comparable in terms of their impact on overall survival. The only clinical data available on markers that are predictive of recurrence and survival after RFA treatment are based on retrospective observational studies. Prospective randomized trials are thus needed to further research in this area. In the present review we analyzed a number of clinical factors that are considered to predict recurrence or survival in HCC patients treated with RFA. We also discussed in detail the circulating biomarkers investigated to date, together with their potential to predict prognosis and recurrence after RFA therapy. Overall survival rates of patients with HCC are significantly affected by liver function, defined as Child-Pugh class, high baseline serum alpha-fetoprotein levels, and the presence of portosystemic collaterals. However, the development of local tumor progression does not significantly affect overall survival. This result is achieved by the effective therapies in patients who relapse after treatment with RFA. For this reason there is an urgent need to identify new circulating biomarkers.

Original languageEnglish
Pages (from-to)44-53
Number of pages10
JournalCritical Reviews in Oncology/Hematology
Volume129
DOIs
Publication statusPublished - Sep 2018

Fingerprint

Hepatocellular Carcinoma
Biomarkers
Recurrence
Survival
Therapeutics
alpha-Fetoproteins
Liver Cirrhosis
Observational Studies
Meta-Analysis
Survival Rate
Retrospective Studies
Liver
Serum
Research
Neoplasms

Keywords

  • Biomarkers/blood
  • Carcinoma, Hepatocellular/blood
  • Catheter Ablation/methods
  • Humans
  • Liver Neoplasms/blood
  • Neoplasm Recurrence, Local/blood
  • Survival Rate
  • Treatment Outcome

Cite this

@article{f8ee166d46af4b10933e67ba6ca722c2,
title = "Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma",
abstract = "Radiofrequency ablation (RFA) is an effective local treatment for curative intent in patients with cirrhosis of the liver and hepatocellular carcinoma (HCC) with diameter <3 cm. Several meta-analyses have shown that RFA and surgical resection are comparable in terms of their impact on overall survival. The only clinical data available on markers that are predictive of recurrence and survival after RFA treatment are based on retrospective observational studies. Prospective randomized trials are thus needed to further research in this area. In the present review we analyzed a number of clinical factors that are considered to predict recurrence or survival in HCC patients treated with RFA. We also discussed in detail the circulating biomarkers investigated to date, together with their potential to predict prognosis and recurrence after RFA therapy. Overall survival rates of patients with HCC are significantly affected by liver function, defined as Child-Pugh class, high baseline serum alpha-fetoprotein levels, and the presence of portosystemic collaterals. However, the development of local tumor progression does not significantly affect overall survival. This result is achieved by the effective therapies in patients who relapse after treatment with RFA. For this reason there is an urgent need to identify new circulating biomarkers.",
keywords = "Biomarkers/blood, Carcinoma, Hepatocellular/blood, Catheter Ablation/methods, Humans, Liver Neoplasms/blood, Neoplasm Recurrence, Local/blood, Survival Rate, Treatment Outcome",
author = "Matteo Canale and Paola Ulivi and Foschi, {Francesco Giuseppe} and Emanuela Scarpi and {De Matteis}, Serena and Gabriele Donati and Giorgio Ercolani and Mario Scartozzi and Luca Faloppi and Alessandro Passardi and Emiliano Tamburini and Martina Valgiusti and Giorgia Marisi and Frassineti, {Giovanni Luca} and {Casadei Gardini}, Andrea",
note = "Copyright {\circledC} 2018 Elsevier B.V. All rights reserved.",
year = "2018",
month = "9",
doi = "10.1016/j.critrevonc.2018.06.017",
language = "English",
volume = "129",
pages = "44--53",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma

AU - Canale, Matteo

AU - Ulivi, Paola

AU - Foschi, Francesco Giuseppe

AU - Scarpi, Emanuela

AU - De Matteis, Serena

AU - Donati, Gabriele

AU - Ercolani, Giorgio

AU - Scartozzi, Mario

AU - Faloppi, Luca

AU - Passardi, Alessandro

AU - Tamburini, Emiliano

AU - Valgiusti, Martina

AU - Marisi, Giorgia

AU - Frassineti, Giovanni Luca

AU - Casadei Gardini, Andrea

N1 - Copyright © 2018 Elsevier B.V. All rights reserved.

PY - 2018/9

Y1 - 2018/9

N2 - Radiofrequency ablation (RFA) is an effective local treatment for curative intent in patients with cirrhosis of the liver and hepatocellular carcinoma (HCC) with diameter <3 cm. Several meta-analyses have shown that RFA and surgical resection are comparable in terms of their impact on overall survival. The only clinical data available on markers that are predictive of recurrence and survival after RFA treatment are based on retrospective observational studies. Prospective randomized trials are thus needed to further research in this area. In the present review we analyzed a number of clinical factors that are considered to predict recurrence or survival in HCC patients treated with RFA. We also discussed in detail the circulating biomarkers investigated to date, together with their potential to predict prognosis and recurrence after RFA therapy. Overall survival rates of patients with HCC are significantly affected by liver function, defined as Child-Pugh class, high baseline serum alpha-fetoprotein levels, and the presence of portosystemic collaterals. However, the development of local tumor progression does not significantly affect overall survival. This result is achieved by the effective therapies in patients who relapse after treatment with RFA. For this reason there is an urgent need to identify new circulating biomarkers.

AB - Radiofrequency ablation (RFA) is an effective local treatment for curative intent in patients with cirrhosis of the liver and hepatocellular carcinoma (HCC) with diameter <3 cm. Several meta-analyses have shown that RFA and surgical resection are comparable in terms of their impact on overall survival. The only clinical data available on markers that are predictive of recurrence and survival after RFA treatment are based on retrospective observational studies. Prospective randomized trials are thus needed to further research in this area. In the present review we analyzed a number of clinical factors that are considered to predict recurrence or survival in HCC patients treated with RFA. We also discussed in detail the circulating biomarkers investigated to date, together with their potential to predict prognosis and recurrence after RFA therapy. Overall survival rates of patients with HCC are significantly affected by liver function, defined as Child-Pugh class, high baseline serum alpha-fetoprotein levels, and the presence of portosystemic collaterals. However, the development of local tumor progression does not significantly affect overall survival. This result is achieved by the effective therapies in patients who relapse after treatment with RFA. For this reason there is an urgent need to identify new circulating biomarkers.

KW - Biomarkers/blood

KW - Carcinoma, Hepatocellular/blood

KW - Catheter Ablation/methods

KW - Humans

KW - Liver Neoplasms/blood

KW - Neoplasm Recurrence, Local/blood

KW - Survival Rate

KW - Treatment Outcome

U2 - 10.1016/j.critrevonc.2018.06.017

DO - 10.1016/j.critrevonc.2018.06.017

M3 - Review article

C2 - 30097237

VL - 129

SP - 44

EP - 53

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

ER -